0RN4 Stock Overview
Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Oncopeptides AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr4.47 |
| 52 Week High | kr11.51 |
| 52 Week Low | kr4.06 |
| Beta | -0.60 |
| 1 Month Change | 3.95% |
| 3 Month Change | -35.60% |
| 1 Year Change | -60.30% |
| 3 Year Change | -96.67% |
| 5 Year Change | -96.36% |
| Change since IPO | -90.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RN4 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -11.1% | -2.4% | -1.4% |
| 1Y | -60.3% | -29.6% | -2.4% |
Return vs Industry: 0RN4 underperformed the UK Biotechs industry which returned -28.5% over the past year.
Return vs Market: 0RN4 underperformed the UK Market which returned -1% over the past year.
Price Volatility
| 0RN4 volatility | |
|---|---|
| 0RN4 Average Weekly Movement | 18.5% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0RN4's share price has been volatile over the past 3 months.
Volatility Over Time: 0RN4's weekly volatility has increased from 12% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 57 | Sofia Heigis | www.oncopeptides.com/sv |
Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is melflufen, a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden
Oncopeptides AB (publ) Fundamentals Summary
| 0RN4 fundamental statistics | |
|---|---|
| Market cap | kr441.46m |
| Earnings (TTM) | -kr249.11m |
| Revenue (TTM) | kr35.22m |
12.5x
P/S Ratio-1.8x
P/E RatioIs 0RN4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RN4 income statement (TTM) | |
|---|---|
| Revenue | kr35.22m |
| Cost of Revenue | -kr1.08m |
| Gross Profit | kr36.30m |
| Other Expenses | kr285.41m |
| Earnings | -kr249.11m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 22, 2024
| Earnings per share (EPS) | -2.52 |
| Gross Margin | 103.06% |
| Net Profit Margin | -707.30% |
| Debt/Equity Ratio | 187.5% |
How did 0RN4 perform over the long term?
See historical performance and comparison